11.73

1.56% 0.18

Bausch Lomb Corp (BLCO)

Overview News Price History Option Chain Financials Discussions Forecast

Bausch Lomb Corp stock is traded at $11.73, with a volume of 679.31K. It is up +1.56% in the last 24 hours and down -0.17% over the past month. Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Previous Close:

$11.55

Open:

$11.94

24h Volume:

679.31K

Relative Volume:

0.81

Market Cap:

$4.45B

Revenue:

$4.79B

Net Income/Loss:

$-317.00M

P/E Ratio:

-12.89

EPS:

-0.91

Net Cash Flow:

$-59.00M

1W Performance:

-4.87%

1M Performance:

-0.17%

6M Performance:

-34.83%

1Y Performance:

-22.27%

1-Day Range:

$11.58

$11.94

1-Week Range:

$11.44

$12.51

52-Week Range:

$10.45

$21.69

Bausch Lomb Corp Stock (BLCO) Company Profile

Name

Bausch Lomb Corp

Sector

Healthcare (1172)

Industry

Medical Instruments & Supplies (61)

Phone

908-541-5456

Address

520 APPLEWOOD CRESCENT, VAUGHAN

Employee

13,500

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

BLCO's Discussions on Twitter

Compare BLCO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLCO Bausch Lomb Corp	11.73	4.45B	4.79B	-317.00M	-59.00M	-0.91
ISRG Intuitive Surgical Inc	509.36	189.82B	8.71B	2.48B	1.75B	6.82
BDX Becton Dickinson Co	168.42	49.98B	20.87B	1.50B	2.59B	5.24
ALC Alcon Inc	85.40	44.00B	9.93B	1.12B	1.58B	2.25
RMD Resmed Inc	253.68	37.05B	5.02B	1.31B	1.56B	8.91
WST West Pharmaceutical Services Inc	215.82	16.36B	2.90B	467.20M	306.90M	6.37

Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-02-25	Reiterated	H.C. Wainwright	Buy
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform
Jul-10-24	Initiated	Raymond James	Outperform
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-12-23	Initiated	Stifel	Hold
Oct-03-23	Resumed	Evercore ISI	Outperform
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight
Sep-12-22	Initiated	H.C. Wainwright	Buy
Jul-26-22	Initiated	RBC Capital Mkts	Outperform
Jun-24-22	Initiated	Evercore ISI	Outperform
Jun-06-22	Initiated	Citigroup	Buy
May-31-22	Initiated	Deutsche Bank	Hold
May-31-22	Initiated	Goldman	Neutral
May-31-22	Initiated	Guggenheim	Buy
May-31-22	Initiated	JP Morgan	Neutral
May-31-22	Initiated	Jefferies	Buy
May-31-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Initiated	Wells Fargo	Overweight
May-11-22	Initiated	Cowen	Outperform

View All

Bausch Lomb Corp Stock (BLCO) Latest News

Jun 18, 2025

Bausch + Lomb prices €675 million in senior secured notes - Investing.com

Jun 18, 2025

Bausch + Lomb Upsizes Note Offering And Secures New Loans - Finimize

Jun 18, 2025

Bausch + Lomb Strengthens Financial Position with €675M Notes and $3.1B Credit Package - Stock Titan

Jun 18, 2025

Bausch + Lomb announces €600m senior secured notes offering - Investing.com

Jun 18, 2025

Jun 17, 2025

Bausch + Lomb Has Promising Growth, But Lower Entry Points Likely Soon - Seeking Alpha

Jun 17, 2025

Jun 14, 2025

Bausch + Lomb’s SWOT analysis: ophthalmology leader faces headwinds in stock outlook - Investing.com

Jun 14, 2025

Jun 10, 2025

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement - BioSpace

Jun 10, 2025

Bausch + Lomb (NYSE:BLCO) Price Target Cut to $16.00 by Analysts at Barclays - Defense World

Jun 10, 2025

Kalkine: Examines Bausch + Lomb (NYSE:BLCO) and Its Dividend Yield Signals - Kalkine Media

Jun 10, 2025

Jun 09, 2025

Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | - GuruFocus

Jun 09, 2025

Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | BLCO Stock News - GuruFocus

Jun 09, 2025

Bausch + Lomb (BLCO) Price Target Reduced by Barclays Analyst | - GuruFocus

Jun 09, 2025

Jun 07, 2025

Barclays reduces Bausch & Lomb stock price target to $16 - Investing.com Australia

Jun 07, 2025

Barclays reduces Bausch & Lomb stock price target to $16 By Investing.com - Investing.com Nigeria

Jun 07, 2025

Jun 06, 2025

BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm - Business Wire

Jun 06, 2025

Jun 04, 2025

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.

Jun 04, 2025

Bausch + Lomb (BLCO) Introduces New Lubricating Eye Drops in U.S - GuruFocus

Jun 04, 2025

Breakthrough Eye Drops: Bausch + Lomb Launches First-Ever Vitamin-Enriched Formula for Dry Eye Relief - Stock Titan

Jun 04, 2025

Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update - Defense World

Jun 04, 2025

Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jun 04, 2025

May 30, 2025